A Phase 2 Study of HB0017 in Psoriasis Patients

Exclusion Criteria

• •Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis
• •Ongoing use of prohibited treatments
• •Any active infection (other than common cold) within 14 days
• •Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization
• •Have previously received any drug that directly targets IL-17 or IL-17 receptor
• •Have concurrent or recent use of any biologic agent within the following washout periods: etanercept \<28 days; infliximab and adalimumab \<60 days; golimumab \< 90 days; anti-IL-12/anti-IL-23 or anti-IL-23p19 antibody drugs \<6 months; or other anti-psoriatic therapy not listed herein within its 5 half-lives prior to randomization
• •A history of inflammatory bowel disease or other serious autoimmune disease
• •Previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency